Socioeconomic status plays major role in opioid pain control

Socioeconomic status plays major role in opioid pain control

Patients in moderate to severe pain in emergency rooms across the U.S. are less likely to receive opioid pain medications if they are black, Hispanic, poor, or have less education, compared to more affluent patients, according to a University of Rochester Medical Center study reported in the Journal of General Internal Medicine.

The study took place against the backdrop of a national epidemic of narcotics abuse, combined with a need to satisfy patients' legitimate complaints of pain.

Racial and are already well-documented in the scientific literature, but the URMC team believes they are the first to investigate whether aspects of socioeconomic status—poverty, income and education levels—also influence the prescription of opioid .

The results point to a need for a national discussion to increase awareness and to provide consistent and unbiased treatments, said corresponding author Robert J. Fortuna, M.D., assistant professor of Medicine and Pediatrics and member of the Center for Primary Care, with a special research interest in improving .

Investigators analyzed a cross-section of data from the National Hospital Ambulatory Care Survey of people 18 and older from 2006 to 2009, which showed that more than 50,000 visits took place at approximately 1,400 emergency departments at which opioids were prescribed. They used zip codes to identify .

(Medications that fall within the opioid class include hydrocodone, e.g., Vicodin; oxycodone, e.g., OxyContin, Percocet; morphine, e.g., Kadian, Avinza; codeine, and related drugs.)

Results confirmed that people of black race or Hispanic ethnicity were less likely to get opioids for equivalent levels of pain. Similarly, people who resided in poorer neighborhoods were less likely to be treated with opioids than those from more affluent areas. For example, patients in the highest income neighborhoods received prescriptions 49 percent of the time for moderate to severe pain, versus 39 percent of the time for patients from lower income areas. Discrepancies also existed among various levels of poverty, with the poorest least likely to get opioids for pain. (Prior studies have documented similar outcomes based on race, even in cases where a patient has a bone fracture.)

Regional differences also were observed, with opioids prescribed more often at emergency departments in the South and West, compared to the Northeast. Although the study was not designed to answer why the disparities occur, the authors said the reasons are complex and should be investigated further. Co-authors Michael Joynt, M.D., and Meghan Train, D.O., a resident in the Department of Medicine at URMC, said that uniform standards and more medical education would help to promote unbiased prescribing.

More information: link.springer.com/article/10.1… 07/s11606-013-2516-z

Related Stories

Missing enzyme linked to drug addiction

Jun 17, 2013

A missing brain enzyme increases concentrations of a protein related to pain-killer addiction, according to an animal study. The results will be presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

User comments